{"id":296235,"date":"2024-08-12T00:00:00","date_gmt":"2024-08-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0013-2022-biopharma-systemic-lupus-erythematosus-access-reimbursement-access-reimbursement\/"},"modified":"2026-04-23T11:20:53","modified_gmt":"2026-04-23T11:20:53","slug":"acreim0013-2024-biopharma-systemic-lupus-erythematosus-access-reimbursement-access-reimbursement-systemic-lupus","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0013-2024-biopharma-systemic-lupus-erythematosus-access-reimbursement-access-reimbursement-systemic-lupus\/","title":{"rendered":"Systemic Lupus Erythematosus &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Systemic Lupus Erythematosus (US)"},"content":{"rendered":"<p>The systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline\u2019s Benlysta, AstraZeneca\u2019s Saphnelo and Aurinia\u2019s Lupkynis are the first for this indication in almost 60 years. Because all approved targeted therapies of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> are expensive, access to it is typically restricted by payers. Several therapies are in late-phase development for <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>. This report examines the prescribing and reimbursement environment for key current therapies and emerging <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> agents in the United States, according to surveyed rheumatologists and <abbr title=\"managed care organization\">MCO<\/abbr> <abbr title=\"pharmacy director\">PD<\/abbr>s \/ <abbr title=\"medical director\">MD<\/abbr>s. The content explores how physicians and payers perceive current and emerging <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> therapies and the reimbursement dynamics that will promote or restrict market access to the agents.<\/p>\n<p><b>Questions <\/b><b>answered<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>What is the extent of <abbr title=\"managed care organization\">MCO<\/abbr> coverage of Benlysta, Saphnelo, Lupkynis, and off-label Rituxan, and how do the coverage policies affect rheumatologists&#8217; prescribing of these drugs? Where do the rituximab biosimilars fit in the <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> treatment algorithm?<\/li>\n<li>Will the approval of Gazyva and Cosentyx for <abbr title=\"lupus nephritis\">LN<\/abbr> affect their coverage on commercial plans? How do rheumatologists perceive these agents for <abbr title=\"lupus nephritis\">LN<\/abbr>, and where in the treatment algorithm do physicians anticipate using them?<\/li>\n<li>How do physicians anticipate using dapirolizumab pegol, litifilimab, upadacitinib, and deucravacitinib which are in development for moderate to severe nonrenal <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>, and how do payers expect to cover these therapies on commercial plans?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geography: United States.<\/p>\n<p>Primary research: Survey of 100 U.S. rheumatologists and 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s).<\/p>\n<p>Key drugs covered: Benlysta, Saphnelo, Lupkynis, Rituxan, rituximab biosimilars, tacrolimus, mycophenolate mofetil, dapirolizumab pegol, litifilimab, upadacitinib Cosentyx, Gazyva.<\/p>\n<p>Reimbursement and contracting.<\/p>\n<p>Access and prescribing.<\/p>\n<p>Special topics.<\/p>\n<p>Opportunities and challenges for emerging therapies.<\/p>\n<p><b>Product description<\/b><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-296235","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296235\/revisions"}],"predecessor-version":[{"id":575924,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296235\/revisions\/575924"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}